{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:04:51Z","timestamp":1794405891457,"version":"4.9.0"},"reference-count":39,"publisher":"American Association for Cancer Research (AACR)","issue":"12","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Accumulating data indicate that tumor-infiltrating regulatory T cells (Treg) are present in human tumors and locally suppress antitumor immune cells. In this study, we found an increased Treg\/CD8 ratio in human breast and cervical cancers. A similar intratumoral lymphocyte pattern was observed in a mouse model for cervical cancer (TC-1 cells). In this model, systemic Treg depletion was inefficient in controlling tumor growth. Furthermore, systemic CTL-associated antigen-4 (CTLA-4) blockade, an approach that can induce tumor immunity in other tumor models, did not result in TC-1 tumor regression but led to spontaneous development of autoimmune hepatitis. We hypothesized that continuous expression of an anti\u2013CTLA-4 antibody localized to the tumor site could overcome Treg-mediated immunosuppression and locally activate tumor-reactive CD8+ cells, without induction of autoimmunity. To test this hypothesis, we created TC-1 cells that secrete a functional anti\u2013CTLA-4 antibody (TC-1\/\u03b1CTLA-4-\u03b31 cells). When injected into immunocompetent mice, the growth of TC-1\/\u03b1CTLA-4-\u03b31 tumors was delayed compared with control TC-1 cells and accompanied by a reversion of the intratumoral Treg\/CD8 ratio due to an increase in tumor-infiltrating IFN\u03b3-producing CD8+ cells. When local anti\u2013CTLA-4 antibody production was combined with Treg inhibition, permanent TC-1 tumor regression and immunity was induced. Importantly, no signs of autoimmunity were detected in mice that received local CTLA-4 blockade alone or in combination with Treg depletion. [Cancer Res 2007;67(12):5929\u201339]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4296","type":"journal-article","created":{"date-parts":[[2007,6,16]],"date-time":"2007-06-16T09:26:18Z","timestamp":1181985978000},"page":"5929-5939","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Combination of Tumor Site\u2013Located CTL-Associated Antigen-4 Blockade and Systemic Regulatory T-Cell Depletion Induces Tumor-Destructive Immune Responses"],"prefix":"10.1158","volume":"67","author":[{"given":"Sebastian","family":"Tuve","sequence":"first","affiliation":[{"name":"1Division of Medical Genetics, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Mae","family":"Chen","sequence":"additional","affiliation":[{"name":"3Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"1Division of Medical Genetics, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Lu","family":"Cheng","sequence":"additional","affiliation":[{"name":"4Faculty of Biomedical Science and Environmental Biology, Kaohsiung Medical University, Kaohsiung, Taiwan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa","family":"Toure\u0301","sequence":"additional","affiliation":[{"name":"5Department of Infectious Diseases, University of Dakar, Dakar, Senegal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa Salif","family":"Sow","sequence":"additional","affiliation":[{"name":"5Department of Infectious Diseases, University of Dakar, Dakar, Senegal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Feng","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Kiviat","sequence":"additional","affiliation":[{"name":"2Department of Pathology, University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Strauss","sequence":"additional","affiliation":[{"name":"1Division of Medical Genetics, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoheng","family":"Ni","sequence":"additional","affiliation":[{"name":"1Division of Medical Genetics, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-Yi","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Medical Genetics, Department of Medicine and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve R.","family":"Roffler","sequence":"additional","affiliation":[{"name":"3Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre\u0301","family":"Lieber","sequence":"additional","affiliation":[{"name":"1Division of Medical Genetics, Department of Medicine and"},{"name":"2Department of Pathology, University of Washington, Seattle, Washington;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,6,15]]},"reference":[{"key":"2022061623211700200_B1","doi-asserted-by":"crossref","unstructured":"Yamaguchi T, Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol\u20082006; 16: 115\u201323.","DOI":"10.1016\/j.semcancer.2005.11.005"},{"key":"2022061623211700200_B2","doi-asserted-by":"crossref","unstructured":"Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med\u20082004; 10: 942\u20139.","DOI":"10.1038\/nm1093"},{"key":"2022061623211700200_B3","doi-asserted-by":"crossref","unstructured":"Woo EY, Yeh H, Chu CS, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol\u20082002; 168: 4272\u20136.","DOI":"10.4049\/jimmunol.168.9.4272"},{"key":"2022061623211700200_B4","doi-asserted-by":"crossref","unstructured":"Viguier M, Lemaitre F, Verola O, et al. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol\u20082004; 173: 1444\u201353.","DOI":"10.4049\/jimmunol.173.2.1444"},{"key":"2022061623211700200_B5","doi-asserted-by":"crossref","unstructured":"Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol\u20082002; 169: 2756\u201361.","DOI":"10.4049\/jimmunol.169.5.2756"},{"key":"2022061623211700200_B6","doi-asserted-by":"crossref","unstructured":"Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood\u20082004; 103: 1755\u201362.","DOI":"10.1182\/blood-2003-07-2594"},{"key":"2022061623211700200_B7","doi-asserted-by":"crossref","unstructured":"Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-\u03b2-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med\u20082005; 202: 919\u201329.","DOI":"10.1084\/jem.20050463"},{"key":"2022061623211700200_B8","doi-asserted-by":"crossref","unstructured":"von Boehmer H. Mechanisms of suppression by suppressor T cells. Nat Immunol\u20082005; 6: 338\u201344.","DOI":"10.1038\/ni1180"},{"key":"2022061623211700200_B9","doi-asserted-by":"crossref","unstructured":"Kohm AP, McMahon JS, Podojil JR, et al. Cutting edge: anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol\u20082006; 176: 3301\u20135.","DOI":"10.4049\/jimmunol.176.6.3301"},{"key":"2022061623211700200_B10","doi-asserted-by":"crossref","unstructured":"Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol\u20082005; 6: 345\u201352.","DOI":"10.1038\/ni1178"},{"key":"2022061623211700200_B11","doi-asserted-by":"crossref","unstructured":"Ko K, Yamazaki S, Nakamura K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med\u20082005; 202: 885\u201391.","DOI":"10.1084\/jem.20050940"},{"key":"2022061623211700200_B12","doi-asserted-by":"crossref","unstructured":"Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol\u20082006; 177: 4376\u201383.","DOI":"10.4049\/jimmunol.177.7.4376"},{"key":"2022061623211700200_B13","doi-asserted-by":"crossref","unstructured":"Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med\u20082000; 192: 295\u2013302.","DOI":"10.1084\/jem.192.2.295"},{"key":"2022061623211700200_B14","doi-asserted-by":"crossref","unstructured":"Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med\u20082000; 192: 303\u201310.","DOI":"10.1084\/jem.192.2.303"},{"key":"2022061623211700200_B15","doi-asserted-by":"crossref","unstructured":"Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol\u20082002; 3: 135\u201342.","DOI":"10.1038\/ni759"},{"key":"2022061623211700200_B16","doi-asserted-by":"crossref","unstructured":"Shimizu J, Yamazaki S, Sakaguchi M. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol\u20081999; 163: 5211\u20138.","DOI":"10.4049\/jimmunol.163.10.5211"},{"key":"2022061623211700200_B17","doi-asserted-by":"crossref","unstructured":"Ikezawa Y, Nakazawa M, Tamura C, Takahashi K, Minami M, Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J Dermatol Sci\u20082005; 39: 105\u201312.","DOI":"10.1016\/j.jdermsci.2005.02.002"},{"key":"2022061623211700200_B18","doi-asserted-by":"crossref","unstructured":"Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood\u20082005; 105: 2862\u20138.","DOI":"10.1182\/blood-2004-06-2410"},{"key":"2022061623211700200_B19","doi-asserted-by":"crossref","unstructured":"Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol\u20082004; 34: 336\u201344.","DOI":"10.1002\/eji.200324181"},{"key":"2022061623211700200_B20","unstructured":"Berd D, Maguire HC, Mastrangelo MJ. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res\u20081986; 46: 2572\u20137."},{"key":"2022061623211700200_B21","doi-asserted-by":"crossref","unstructured":"Matar P, Rozados VR, Gervasoni SI, Scharovsky GO. Th2\/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother\u20082002; 50: 588\u201396.","DOI":"10.1007\/s00262-001-0237-3"},{"key":"2022061623211700200_B22","doi-asserted-by":"crossref","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science\u20081996; 271: 1734\u20136.","DOI":"10.1126\/science.271.5256.1734"},{"key":"2022061623211700200_B23","unstructured":"Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res\u20082000; 60: 2444\u20138."},{"key":"2022061623211700200_B24","doi-asserted-by":"crossref","unstructured":"van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med\u20081999; 190: 355\u201366.","DOI":"10.1084\/jem.190.3.355"},{"key":"2022061623211700200_B25","doi-asserted-by":"crossref","unstructured":"Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med\u20081996; 184: 783\u20138.","DOI":"10.1084\/jem.184.2.783"},{"key":"2022061623211700200_B26","doi-asserted-by":"crossref","unstructured":"Luhder F, Chambers C, Allison JP, Benoist C, Mathis D. Pinpointing when T cell costimulatory receptor CTLA-4 must be engaged to dampen diabetogenic T cells. Proc Natl Acad Sci U S A\u20082000; 97: 12204\u20139.","DOI":"10.1073\/pnas.200348397"},{"key":"2022061623211700200_B27","doi-asserted-by":"crossref","unstructured":"Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB\/c mice. Proc Natl Acad Sci U S A\u20082002; 99: 3013\u20137.","DOI":"10.1073\/pnas.042684699"},{"key":"2022061623211700200_B28","doi-asserted-by":"crossref","unstructured":"Maker AV, Attia P, Rosenberg SA. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol\u20082005; 175: 7746\u201354.","DOI":"10.4049\/jimmunol.175.11.7746"},{"key":"2022061623211700200_B29","doi-asserted-by":"crossref","unstructured":"Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol\u20082002; 3: 611\u20138.","DOI":"10.1038\/ni0702-611"},{"key":"2022061623211700200_B30","doi-asserted-by":"crossref","unstructured":"Kataoka H, Takahashi S, Takase K, et al. CD25(+)CD4(+) regulatory T cells exert in vitro suppressive activity independent of CTLA-4. Int Immunol\u20082005; 17: 421\u20137.","DOI":"10.1093\/intimm\/dxh221"},{"key":"2022061623211700200_B31","doi-asserted-by":"crossref","unstructured":"Di Paolo NC, Tuve S, Ni S, Hellstrom KE, Hellstrom I, Lieber A. Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. Cancer Res\u20082006; 66: 960\u20139.","DOI":"10.1158\/0008-5472.CAN-05-2388"},{"key":"2022061623211700200_B32","doi-asserted-by":"crossref","unstructured":"Kocak E, Lute K, Chang X, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res\u20082006; 66: 7276\u201384.","DOI":"10.1158\/0008-5472.CAN-05-2128"},{"key":"2022061623211700200_B33","doi-asserted-by":"crossref","unstructured":"Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihir K, Toge T. Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer\u20082006; 106: 1227\u201336.","DOI":"10.1002\/cncr.21729"},{"key":"2022061623211700200_B34","doi-asserted-by":"crossref","unstructured":"DeLong P, Carroll RG, Henry AC, et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther\u20082005; 4: 342\u20136.","DOI":"10.4161\/cbt.4.3.1644"},{"key":"2022061623211700200_B35","doi-asserted-by":"crossref","unstructured":"Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol\u20082005; 6: 353\u201360.","DOI":"10.1038\/ni1181"},{"key":"2022061623211700200_B36","doi-asserted-by":"crossref","unstructured":"Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study. Ann Surg Oncol\u20082005; 12: 1005\u201316.","DOI":"10.1245\/ASO.2005.03.536"},{"key":"2022061623211700200_B37","doi-asserted-by":"crossref","unstructured":"Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A\u20082003; 100: 8372\u20137.","DOI":"10.1073\/pnas.1533209100"},{"key":"2022061623211700200_B38","doi-asserted-by":"crossref","unstructured":"Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med\u20082001; 194: 823\u201332.","DOI":"10.1084\/jem.194.6.823"},{"key":"2022061623211700200_B39","doi-asserted-by":"crossref","unstructured":"Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest\u20082006; 116: 1935\u201345.","DOI":"10.1172\/JCI27745"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/12\/5929\/2569779\/5929.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/12\/5929\/2569779\/5929.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:30:44Z","timestamp":1683876644000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/12\/5929\/533155\/Combination-of-Tumor-Site-Located-CTL-Associated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6,15]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2007,6,15]]},"published-print":{"date-parts":[[2007,6,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4296","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22367423.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367420","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367426.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367423","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367411","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367414","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367426","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367429","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367420.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367411.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367429.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367414.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495542","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495542.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,6,15]]}}}